A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Domestic Sales of Ethical Drugs Rose 0.3% to 9,560.1 Billion Yen in FY2012: IMS Japan
May 22, 2013
-
BUSINESS Allegra AGs Pitched as Affordable Original Drugs with Production by Sanofi
May 21, 2013
-
BUSINESS Takeda Slips to 3rd Place in 25 Major Pharmas’ Operating Profit Ranking
May 20, 2013
-
BUSINESS FY2012 Sales Up 18% for Both Generic-Only Makers, Research-Driven Pharmas’ Generic Units; Govt Incentive Measures Biggest Contributor
May 17, 2013
-
BUSINESS FY2012 Japan Pharma Market: Sales of Major Long-Listed Drugs Tumble 30-40%
May 16, 2013
-
REGULATORY CSIMC Approves Listing of 15 New APIs/19 Products Including Pfizer’s Xeljanz with Expected Peak Sales of 59.7 Billion Yen
May 16, 2013
-
BUSINESS Eight Companies Initiate Voluntary Recall of Enalapril Generics Due to Deviations from Specifications
May 15, 2013
-
BUSINESS Four Leading Wholesalers See Clear Recovery in Pharmaceutical Wholesale Business
May 14, 2013
-
REGULATORY PMDA-WEST to Be Launched in Osaka in October to Undertake Consultation Services, GMP Inspections
May 13, 2013
-
BUSINESS MTPC Royalties Reach 19.5 Billion Yen from Out-Licensed Gilenya
May 10, 2013
-
BUSINESS Takeda Sees Sales Rise on Expanding Europe, Emerging Market Biz in FY2012, Yet Operating Profit Sags 50%
May 10, 2013
-
BUSINESS No Prospects of Reaching Agreement on Delivery Prices with Wholesalers Even after the Fiscal Year End: Pres. Tajiri of Medical System Network
May 10, 2013
-
BUSINESS Takeda to Acquire US Dengue Vaccine Developer Inviragen
May 9, 2013
-
BUSINESS IFRS Implications to Be Seen in In-Licensed Products, M&A Processing
May 9, 2013
-
ORGANIZATION Kyokai Kenpo Launches Trial Notification Service on Copayment Differences between Original, Generic Anti-Allergy Drugs
May 8, 2013
-
ACADEMIA Nat’l University Hospitals Sharing Information of Drug Purchase Prices through Central Database
May 7, 2013
-
BUSINESS Boehringer to Enter Oncology Market, Hire 100 MRs in Japan
May 2, 2013
-
BUSINESS Novartis Investigating Employee Involvement in Retracted Diovan Papers
May 1, 2013
-
REGULATORY First Committee Recommends Approval for New Gout, Hyperuricemia Treatment, Antihypertensive Tape Formulation
May 1, 2013
-
REGULATORY PMRJ Introduces “RS Expert Certification System”
April 30, 2013
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…